Skip to main content
. Author manuscript; available in PMC: 2023 Feb 4.
Published in final edited form as: N Engl J Med. 2022 Aug 4;387(5):397–407. doi: 10.1056/NEJMoa2203067

Figure 1. Enrollment, Administration of L9LS, and Controlled Human Malaria Infection.

Figure 1.

Trial enrollment occurred from September 13 to October 25, 2021. Controlled human malaria infection occurred on October 26, 2021. All participants who received L9LS were followed for 24 weeks after administration of L9LS. Control participants were followed for 7 weeks after controlled human malaria infection (CHMI).